Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 1.00 |
| ▸ | MAOB | P27338 | 9/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.54 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755876 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAHTR2CKCNH2 | |
| SCHEMBL18596475 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAHTR2CKCNH2 | |
| SCHEMBL5729043 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAHTR2CKCNH2 | |
| Hydrochloric Acid SCHEMBL15091706 | 0.98 | KDM1A (1.00) | KDM1AMAOBMAOAHTR2CKCNH2 | |
| Hydrochloric Acid SCHEMBL15091705 | 0.98 | KDM1A (1.00) | KDM1AMAOBMAOAHTR2CKCNH2 | |
| SCHEMBL12971942 | 0.94 | KDM1A (0.89) | KDM1AMAOBMAOAHTR2CKCNH2 | |
| SCHEMBL11064726 | 0.84 | KDM1A (0.72) | KDM1AMAOBMAOAHTR2CSLC6A2 | |
| SCHEMBL11064728 | 0.84 | KDM1A (0.72) | KDM1AMAOBMAOAHTR2CSLC6A2 | |
| SCHEMBL4257203 | 0.80 | KDM1A (0.67) | KDM1AMAOBMAOAHTR2CSLC6A2 | |
| SCHEMBL4266649 | 0.80 | KDM1A (0.67) | KDM1AMAOBMAOAHTR2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779096-B | Fluorine-substituted cyclopropylamine compounds, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | disclosed |
| EP-3431471-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-01-23 | — | — | EP | disclosed |
| CN-108779096-A | A kind of fluorine-substituted cyclopropylamine class compound and preparation method thereof, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2018-11-09 | — | — | CN | disclosed |
| CN-107200706-A | Cyclopropylamine class compound of one class fluorine substitution and preparation method thereof, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2017-09-26 | — | — | CN | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389580-B2 | Arylcyclopropylamines and methods of use | DUKE UNIVERSITY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOB 34/4885MAOA 39/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOB 34/4885MAOA 39/4885 |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SETDB1, KDM1B, SETD7 | KDM1A 4/4885MAOB 323/4885MAOA 351/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | KDM1A 1587/4885MAOB 544/4885MAOA 383/4885 |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | KDM1A 14/4885MAOB 2/4885MAOA 1/4885 |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SETDB1, KDM1B, SETD7 | KDM1A 4/4885MAOB 323/4885MAOA 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.